Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

February 27, 2021 1 min read

ID: 3

Discovery Date: 27 February 2021, 01:00:00 UTC

Published Date: 2021-02-15 17:00:00

Source: Clinical Trials.gov

Link: https://clinicaltrials.gov/ct2/show/NCT04754594?term=biontech&sfpd_d=14&sel_rss=new14

Abstract

Conditions: SARS-CoV-2 Infection; COVID-19; Maternal Immunization
Interventions: Biological: BNT162b2; Other: Placebo
Sponsors: BioNTech SE; Pfizer
Not yet recruiting

Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Abstract

Noun Phrases in Title